US11788086B2ActiveUtilityA1

Antitumor compounds and tumor diagnosis

37
Assignee: CBMED GMBH CENTER FOR BIOMARKER RES IN MEDICINEPriority: Aug 3, 2016Filed: Jul 27, 2017Granted: Oct 17, 2023
Est. expiryAug 3, 2036(~10 yrs left)· nominal 20-yr term from priority
Inventors:Johannes HaybaeckNicole Golob-SchwarzlStefanie KrassnigNadine ThalerJulia Judith UnterluggauerAlexander Deutsch
G01N 33/57595G01N 33/57557G01N 33/57535G01N 33/5752C12N 15/113C12Q 1/6886G01N 33/57407G01N 33/57419G01N 33/57423G01N 33/57496C12N 2310/14C12Q 2600/118C12Q 2600/158C12N 2310/531
37
PatentIndex Score
0
Cited by
23
References
6
Claims

Abstract

The present invention relates to a eukaryotic initiation factor (eIF) modulating compound for use in the treatment of a tumor and in the diagnosis of a cancer. The present invention also relates to a method of diagnosing lung cancer in an individual and to a method of providing a prognosis to an individual suffering from lung cancer. Furthermore, the present invention relates to a method of diagnosing colorectal cancer in an individual, a method of differentiating between colon cancer (CC) and rectum cancer (RC) in an individual, a method of determining whether an individual responds to a therapeutic treatment of colorectal cancer, and to a method of determining the course of colorectal cancer in an individual. Furthermore, the present invention relates to a method of diagnosing a glioma in an individual, a method of grading a glioma in an individual, a method of differentiating between a low-grade glioma and a high-grade glioma in an individual, a method of determining whether an individual responds to a therapeutic treatment of a glioma, and a method of determining the course of a glioma in an individual. In addition, the present invention relates to a kit for conducting the above mentioned methods.

Claims

exact text as granted — not AI-modified
The invention claimed is: 
     
       1. A method for treating lung adenocarcinoma, comprising the step of:
 administering a eukaryotic initiation factor 6 (eIF6) small interfering RNA (siRNA) to a patient having lung adenocarcinoma, wherein the eIF6 siRNA comprises SEQ ID NO:5 or 6. 
 
     
     
       2. The method according to  claim 1 , wherein the eIF6 siRNA comprises SEQ ID NO:5. 
     
     
       3. The method according to  claim 1 , wherein the eIF6 siRNA comprises SEQ ID NO:6. 
     
     
       4. The method according to  claim 1 , wherein the eIF6 siRNA consists of SEQ ID NO:5. 
     
     
       5. The method according to  claim 1 , wherein the eIF6 siRNA consists of SEQ ID NO:6. 
     
     
       6. The method of  claim 1 , wherein the eIF6 siRNA is administered by intravenous, intramuscular, intrathecal, subcutaneous, transdermal or aerosol administration.

Join the waitlist — get patent alerts

Track US11788086B2 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.